Non-Hodgkin Lymphoma Highlights From SOHO 2023

Loretta J. Nastoupil, MD


September 27, 2023

Highlights in non-Hodgkin lymphoma from the Society of Hematologic Oncology (SOHO) 2023 annual meeting, including studies on chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, and mosunetuzumab retreatment, are discussed by Dr Nastoupil of MD Anderson Cancer Center.

First, Dr Nastoupil discusses the phase 2 TRANSCEND FL study, which she presented at the conference. The study explored the CAR-T therapy lisocabtagene maraleucel (liso-cel) for relapsed/refractory follicular lymphoma. The results, she anticipates, will probably lead to US Food and Drug Administration (FDA) approval of liso-cel for this indication.

She then examines early data on mosunetuzumab and retreatment, which suggested that patients whose disease recurs can be successfully rechallenged with this CD20/CD3 bispecific antibody without any new safety signal.

Next, Dr Nastoupil looks at updates on a phase 2 study that combined CD20/CD3 bispecific antibodies with lenalidomide and rituximab. The objective response rate was high, but she commented that longer follow-up is needed.

She then discusses a study showing a durable response with epcoritamab in large cell lymphoma after longer follow-up.

Finally, Dr Nastoupil reviews a study on liso-cel in relapsed/refractory mantle cell lymphoma that resulted in very high response rates. The research may yield an FDA approval of liso-cel for mantle cell lymphoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.